evipedia.ai
← Back

Low-Dose Naltrexone for Health & Longevity

Evidence Review created on 08/30/2026 using AI4L / Opus 5

Also known as: LDN, Low Dose Naltrexone, Naltrexone (Low-Dose), Naltrexone Hydrochloride

Motivation

Naltrexone is a prescription medicine that blocks the body’s opioid receptors — the docking points used by morphine and by the body’s own pain-relieving chemicals. At the licensed dose it is used in addiction treatment. At roughly one-tenth that amount, taken as a single daily capsule, it appears to behave like a different drug: the brief blockade seems to quiet inflammatory signalling in the nervous system and nudge the immune system toward balance.

The low-dose approach began in the 1980s with a New York physician treating patients with damaged immunity, and has since spread through compounding pharmacies, integrative clinics and longevity practices to conditions as varied as widespread muscle pain, inflammatory bowel disease and lingering illness after infection. Because the drug is inexpensive and no longer under patent, little money has been spent on large confirmatory studies, and the published record remains far smaller than the range of uses claimed for it.

This review examines what the human evidence shows about low-dose naltrexone — what the controlled studies set out to measure and what they found, what is known about its safety over months and years, and how it is dosed, sourced and monitored in practice.

Benefits - Risks - Protocol - Conclusion

High-level overviews from clinicians and researchers who work with this compound directly, chosen for practical or mechanistic depth rather than for restating trial results.

Of the priority sources, Rhonda Patrick (foundmyfitness.com) and Life Extension (lifeextension.com) carry no article or episode devoted to low-dose naltrexone. A site search of foundmyfitness.com returns no results at all. Life Extension covers the compound only inside disease-specific protocol pages — a dedicated section within its cancer drug-repurposing protocol, and passing mentions elsewhere — which address a single indication rather than giving the high-level overview of the intervention required here.

Grokipedia

Low-dose naltrexone

A densely referenced entry on the low-dose use itself, covering the competing opioid growth factor (a brake on cell division) and Toll-like receptor (an immune sensor) accounts, the 1–5 mg range, and safety.

Examine

No Examine article exists for low-dose naltrexone. A direct search of examine.com for “naltrexone” returned no results at all. Examine.com covers dietary supplements and does not typically cover prescription medications, and low-dose naltrexone is available only on prescription from a compounding pharmacy.

ConsumerLab

No ConsumerLab article exists for low-dose naltrexone. A direct search of consumerlab.com for “naltrexone” returned no dedicated page, only a passing reference inside an answer about palmitoylethanolamide. ConsumerLab tests dietary supplements for identity and purity and does not typically cover prescription medications.

Systematic Reviews

These are the systematic reviews and meta-analyses that define the current evidence base, covering both the claimed benefits and the safety side of the trade-off.

Mechanism of Action

Naltrexone is a competitive antagonist at the μ-, δ- and κ-opioid receptors (the three main docking sites for opioid signalling), with greatest affinity for μ. Two mechanisms are proposed for the 1–5 mg range.

The first is rebound. Because naltrexone’s plasma half-life is roughly 4 hours and that of its active metabolite 6-β-naltrexol roughly 13 hours, a small dose blocks the receptors only briefly; the body responds by increasing endogenous opioid peptides and by upregulating the opioid growth factor receptor (OGFr, a nuclear receptor that restrains cell division), an axis characterised over three decades by Zagon and McLaughlin.

The second is independent of opioid receptors entirely: naltrexone antagonises Toll-like receptor 4 (TLR4, an immune sensor that switches on inflammation) on microglia and macrophages, reducing release of pro-inflammatory signalling proteins.

The two accounts compete. Metz and colleagues found in mice that low-dose naltrexone did not change β-endorphin release or the excitability of proopiomelanocortin neurons (the cells that make the body’s principal endorphin), arguing the rebound story cannot explain the reported mood and pain effects. The glial account fits the dose-response pattern better but rests largely on cell and animal work.

Naltrexone undergoes extensive first-pass metabolism, primarily by the cytosolic aldo-keto reductase AKR1C4 (the enzyme that reduces its ketone group) rather than by cytochrome P450 enzymes such as CYP3A4 (a liver enzyme that metabolises many drugs), then glucuronidation (a liver step that makes the drug water-soluble) and renal excretion. It distributes widely and crosses the blood–brain barrier.

Historical Context & Evolution

Naltrexone was synthesised in 1963 and licensed by the U.S. Food and Drug Administration (FDA, the American medicines regulator) in 1984 for opioid dependence and in 1994 for alcohol dependence, at 50 mg daily. The purpose was blockade: at that dose opioids produce little effect and alcohol loses much of its reward.

The low-dose use arose separately. In the mid-1980s Bernard Bihari, a New York physician working with patients with acquired immunodeficiency, observed that they carried low circulating endorphin levels, and reported that 1.75–4.5 mg at bedtime raised those levels and improved lymphocyte counts. He extended the practice to cancer and autoimmune disease. In parallel, Ian Zagon and Patricia McLaughlin at Penn State characterised the opioid growth factor axis, giving the practice a mechanistic frame.

Controlled work followed slowly. Jill Smith’s Crohn’s disease trial reported symptom improvement and healing at colonoscopy; Jarred Younger and Sean Mackey’s fibromyalgia crossover trial reported reduced daily pain; a multiple sclerosis crossover trial reported better mental-health quality of life. All were small, and several were single-centre crossover designs.

Because the compound came off patent, no sponsor had reason to fund confirmatory trials, and the literature stayed small and investigator-initiated. Two adequately powered parallel-group trials — in Denmark and in Spain — have since failed to separate from placebo on pain. The field is now openly divided rather than settled, and the earlier positive findings have not been retracted or explained away.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every outcome measured in more than one randomised trial — pain intensity in fibromyalgia, quality of life in multiple sclerosis, depressive symptoms — yields conflicting results across those trials, and every other indication rests on a single small randomised trial, on uncontrolled case series, or on animal work.

Medium 🟩 🟩

Clinical and Colonoscopy Response in Active Crohn’s Disease

In active Crohn’s disease, 4.5 mg daily produced a higher rate of symptom response and of visible healing of the bowel lining than placebo. The proposed mechanism is restraint of mucosal inflammation and promotion of epithelial repair through the opioid growth factor axis. The evidence base is a Cochrane review of two randomised trials in 46 participants; only the adult trial, with 34 participants, tested efficacy, and Cochrane graded the certainty low for serious imprecision. No confirmatory trial has been run since.

Magnitude: In the Cochrane analysis, 83% of treated adults reached a 70-point fall in the Crohn’s Disease Activity Index (a standard symptom score) versus 38% on placebo — risk ratio (RR, how many times more likely an outcome is on treatment) 2.22, 95% confidence interval (CI, the range in which the true value most plausibly lies) 1.14 to 4.32. For response at colonoscopy the figures were 72% versus 25%, RR 2.89, 95% CI 1.18 to 7.08.

Low 🟩

Pain Reduction in Fibromyalgia ⚠️ Conflicted

Two small crossover trials and three meta-analyses report less daily pain on 4.5 mg; the two largest parallel-group trials, in Denmark and in Spain, found no separation from placebo over 12 weeks and 12 months. Net reading: any average effect is small and not reliably reproduced in adequately powered designs.

Magnitude: Meta-analysis of five randomised trials gives a standardised mean difference (SMD, an effect expressed in standard deviations) of −0.61 for pain, 95% CI −1.14 to −0.08. The 99-participant Danish trial found −0.34 points on an 11-point scale, 95% CI −0.95 to 0.27, and the 98-participant Spanish trial +0.49 points; neither reached significance.

Mental-Health Quality of Life in Multiple Sclerosis ⚠️ Conflicted

One crossover trial in 80 people with multiple sclerosis improved mental-health quality-of-life scores; a parallel-group trial in 96 people found no difference on any domain except health perception. Net reading: the signal is confined to self-reported mental-health measures in a single under-powered study.

Magnitude: A 3.3-point gain on the Short Form-36 Mental Component Summary and 6 points on the Mental Health Inventory over 8 weeks, both validated scales. The larger trial reported no between-group difference in pain, energy, emotional well-being, cognition or overall quality of life.

Reduced Fatigue and Improved Daily Function After Infection

Pooled before-and-after data from four uncontrolled studies in 155 people with persistent symptoms after COVID-19 show moderate reductions in fatigue and mental fogginess and larger gains in pain and daily functioning. No randomised trial exists; in this design, expectation effects cannot be separated from drug effects.

Magnitude: Pooled effect sizes (Hedges’ g, an effect size corrected for small samples) of −0.74 for fatigue, −0.53 for mental fogginess, −0.60 for sleep quality, and −0.93 for both pain and daily functioning, all favouring treatment. Disagreement between the studies (heterogeneity) ranged from 0% to 62%.

Symptom Relief in Complex Regional Pain Syndrome and Other Centralised Pain

A systematic review and a scoping review describe reduced pain and abnormal muscle contraction in complex regional pain syndrome (a limb pain disorder that follows injury), plus benefit in burning mouth syndrome and pelvic pain, all uncontrolled. In diabetic nerve pain a randomised trial matched amitriptyline.

Magnitude: A fourteen-year Mayo Clinic series of 115 patients prescribed low-dose naltrexone for mixed chronic pain found 65% reported benefit at follow-up, with no comparator group. In painful diabetic neuropathy the difference from amitriptyline in visual analogue pain score was 1.64 points, 95% CI −0.92 to 4.20, so neither drug separated from the other.

Improvement in Inflammatory Skin Disease

Reports in psoriasis, Hailey-Hailey disease (a rare blistering skin disorder), scarring hair loss and itch describe clearance of lesions or relief of itching at 1.5–6 mg. The evidence is a systematic review, a review in scarring alopecia and one small open trial. Publication bias toward successes is likely.

Magnitude: The direction is consistently toward improvement, holding mainly in itch-dominant and hair-follicle conditions rather than in plaque disease. The reviews report no pooled outcome figure, because the underlying literature consists of case reports and uncontrolled series rather than controlled trials.

Reduction of Depressive Symptoms ⚠️ Conflicted

A 12-person proof-of-concept trial in people whose depression broke through dopamine-acting antidepressants reported lower rating-scale scores on 1 mg twice daily; a larger 37-person trial adding 4.5 mg to existing treatment found nothing. Net reading: the positive signal has not survived a better-powered test.

Magnitude: In the 12-person trial, depression rating-scale scores fell 18 points on low-dose naltrexone against 8 on placebo, an effect size of 1.45. In the 37-person trial the falls were 10.5 and 9.8 points, indistinguishable from each other.

Speculative 🟨

Extension of Healthspan and Lifespan

In Caenorhabditis elegans, low but not high naltrexone doses extended lifespan and healthspan through SKN-1 (the worm counterpart of human NRF2 stress-response signalling). The basis is animal work only; no human data exist.

Improved Insulin Sensitivity in Metabolic Inflammation

In cell and mouse models, low-dose naltrexone restored SIRT1 (a metabolic regulator enzyme) and blocked NF-κB (the main inflammatory gene switch), reversing insulin resistance. The basis is animal only; no human trial exists.

Restraint of Tumour Growth

Cell-culture and rodent work reports dose-dependent inhibition of tumour cell growth through the opioid growth factor axis. A systematic review found the human evidence limited to case reports, so the basis remains anecdotal.

Benefit-Modifying Factors

  • Genetic variation in opioid receptor signalling: The OPRM1 A118G variant (rs1799971, which alters the μ-opioid receptor) predicts naltrexone response in alcohol dependence. Whether it modifies low-dose effects is untested, and no validated pharmacogenetic test exists for this use.

  • Baseline inflammatory markers: In the fibromyalgia pilot study, the erythrocyte sedimentation rate (ESR, a blood test that rises with inflammation) before treatment predicted over 80% of the variation in response — higher values, larger benefit. The finding has not been replicated.

  • Sex: Nearly all fibromyalgia trial participants were women, so efficacy estimates apply chiefly to women. The Crohn’s disease and multiple sclerosis trials enrolled both sexes but reported no sex-stratified results, leaving the question open.

  • Pre-existing inflammatory or autoimmune disease: Benefit signals concentrate in conditions with active immune dysregulation — Crohn’s disease, centralised pain states, illness after infection. In people without such a condition, no human outcome data support any benefit at all.

  • Age: Trials enrolled mainly adults between 30 and 65. Above 65, reduced hepatic clearance, greater sleep fragility and higher medication burden argue for lower starting doses; no trial has reported outcomes stratified by age.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Sleep Disruption and Vivid Dreams

The most consistently reported effect is intense, memorable dreaming and difficulty falling asleep in the first weeks. The proposed mechanism is opioid-receptor blockade during the overnight endorphin peak when the dose is taken at bedtime. It appears across randomised fibromyalgia trials, in both Crohn’s disease trials, and in clinical series. It is mild, usually transient, and generally resolves on dose reduction or by moving the dose to the morning. It is the commonest reason for early discontinuation among people who otherwise tolerate the drug.

Magnitude: Meta-analysis of five randomised trials puts the incidence of vivid dreams at 2.41 times that of placebo, 95% CI 1.77 to 3.28. Insomnia was reported by a minority of participants in the fibromyalgia pilot studies and described there as minor and transient.

Nausea and Gastrointestinal Upset

Nausea, and less often loose stools or abdominal discomfort, occurs in the first days of treatment and after each dose increase. The mechanism is direct opioid-receptor blockade in the gut wall and in the brainstem area that triggers vomiting. It appears more often than placebo in pooled randomised fibromyalgia data and is a recognised effect of naltrexone at every dose. It is dose-related and typically settles within one to two weeks; lowering or splitting the dose usually resolves it.

Magnitude: Across seven randomised chronic-pain trials the overall adverse-event rate exceeded placebo — incidence rate ratio (IRR, the ratio of event rates between two groups) 1.4, 95% CI 1.12 to 1.75. Nausea specifically was significantly more frequent than placebo in the pooled fibromyalgia meta-analysis.

Loss of Opioid Analgesia and Precipitated Withdrawal

Because naltrexone occupies opioid receptors, it blocks opioid analgesics and, in anyone physically dependent on opioids, can precipitate abrupt withdrawal — sweating, vomiting, cramping, agitation. Onset is within hours; severity ranges from uncomfortable to requiring hospital care. The evidence is randomised trial and post-marketing data at the 50 mg dose, reflected in the labelled contraindication. A Mayo Clinic series found low-dose co-prescription with opioids was tolerated in practice, so the threshold dose is not established.

Magnitude: Not quantified in available studies. Trials of low-dose naltrexone exclude opioid users by protocol, so no controlled estimate of withdrawal incidence at 1–4.5 mg exists, and the risk is inferred from receptor pharmacology and from the labelled contraindication at the standard dose.

Medium 🟥 🟥

Non-Response and Early Discontinuation

The practical risk for this audience is committing months and money to a therapy that a substantial minority abandon. In a fourteen-year Mayo Clinic review of 115 patients prescribed it for pain, a third had stopped by last follow-up, adverse effects accounting for only part of that. Randomised trials show withdrawal for adverse events close to placebo rates, so the burden reflects disappointed expectation more than toxicity.

Magnitude: 36% had stopped by most recent follow-up in the Mayo Clinic series, with adverse effects reported by 11 of 115 patients (11%). In the Danish randomised trial, discontinuation for adverse events was 8% on drug versus 6% on placebo.

Low 🟥

Liver Enzyme Elevation ⚠️ Conflicted

Naltrexone carried an FDA boxed warning for hepatotoxicity until 2013, after liver enzymes rose at 300 mg; an early case report reinforced it. The 89-trial meta-analysis found no excess of serious adverse events at any dose, and a cirrhosis cohort none. Net reading: at 1–4.5 mg hepatic risk appears negligible.

Magnitude: No dose-related liver enzyme elevation has been demonstrated below 50 mg. The literature reports no outcome figure at low dose, because the trials that measured liver enzymes at 1–4.5 mg were too small to estimate an event rate.

Attenuation of Ketamine’s Antidepressant Effect

A randomised crossover trial found naltrexone pretreatment blocked ketamine’s antidepressant response, a follow-up extended this to antisuicidal effects, and a 2025 crossover study examined the same interaction. All used the 50 mg dose; the low-dose case is indirect but mechanistically continuous.

Magnitude: Depression rating scores did not improve at all under naltrexone pretreatment while the same participants improved substantially under placebo pretreatment. No study has measured the interaction at 1–4.5 mg, so no low-dose figure is reported in the literature.

Destabilisation of Thyroid Hormone Replacement ⚠️ Conflicted

Clinicians treating autoimmune thyroid disease report that as inflammation settles, a previously correct levothyroxine dose becomes excessive, causing palpitations and insomnia. A Norwegian registry study found no change in thyroid hormone dispensing after starting the drug. Net reading: if real, the effect is uncommon.

Magnitude: In the Norwegian registry study, dispensed thyroid hormone quantities were unchanged in the year after starting low-dose naltrexone compared with the year before. No trial has measured thyroid-stimulating hormone before and after treatment, so the literature reports no individual-level figure.

Speculative 🟨

Blunting of Exercise- and Reward-Related Endorphin Signalling

Endogenous opioids are one proposed contributor to post-exercise mood elevation, so receptor blockade could theoretically damp it, though a controlled trial found exercise-induced pain relief survives 50 mg naltrexone. No study has tested low doses.

Risk-Modifying Factors

  • Genetic and enzymatic variation: Naltrexone is cleared by aldo-keto reductase and glucuronidation rather than by cytochrome P450 enzymes, so common cytochrome variants matter little. Reduced UGT (the glucuronidation enzyme family) activity may raise exposure but is unstudied at low dose.

  • Baseline liver enzymes: Raised alanine aminotransferase before starting warrants caution and a recheck, since dose-related enzyme elevation is documented at 50 mg and above, and a pre-existing rise removes the headroom for interpreting later changes.

  • Sex: Adverse-event rates in the randomised trials did not differ meaningfully by sex, but the fibromyalgia trials were almost entirely female, which limits confidence in the tolerability estimate for men.

  • Pre-existing health conditions: Opioid dependence, acute hepatitis or decompensated cirrhosis, and treated autoimmune thyroid disease each raise risk substantially. Chronic kidney disease slows clearance of the active metabolite 6-β-naltrexol.

  • Age: Older adults carry more concurrent medications and far more opioid prescriptions, which raises both interaction risk and the chance of unrecognised opioid exposure at initiation, the one avoidable serious harm.

Key Interactions & Contraindications

  • Opioid analgesics: Absolute contraindication with full agonists (morphine, oxycodone, hydrocodone, fentanyl, tramadol, codeine). Consequence: blocked analgesia and precipitated withdrawal. Mitigation: 7–10 opioid-free days before the first dose, and disclosure before any surgery.

  • Over-the-counter opioid-containing preparations: Caution with loperamide and, where sold without prescription, codeine-containing cough and pain products. Consequence: loss of antidiarrhoeal or cough-suppressing effect. No dose adjustment restores it; substitution of a non-opioid agent is the only workaround.

  • Kratom and other partial opioid agonists: Absolute contraindication in regular users. Consequence: precipitated withdrawal within hours, since kratom’s alkaloids act at the same receptor. Mitigation: the same 7–10 day washout as prescription opioids.

  • Ketamine and esketamine: Caution. Consequence: attenuated antidepressant and antisuicidal response, shown in randomised crossover studies at standard naltrexone dose. Mitigation: separation of the two courses in time rather than co-administration, and disclosure to the treating clinician.

  • Thyroid hormone replacement: Monitor. Consequence: as autoimmune thyroid inflammation settles, the previous levothyroxine or desiccated thyroid dose can become excessive, causing palpitations, heat intolerance and insomnia. Mitigation: a thyroid-stimulating hormone recheck every 6–12 weeks.

  • Disulfiram: Caution. Consequence: both agents carry hepatic signals, so additive liver enzyme elevation is plausible. Mitigation: alanine and aspartate aminotransferase measured at 4 and 12 weeks where the two are combined.

  • Bupropion: Caution. Consequence: the fixed naltrexone–bupropion weight-loss combination lowers the seizure threshold, and adding separate low-dose naltrexone duplicates one component. Mitigation: a review of total naltrexone exposure to avoid duplication.

  • Additive anti-inflammatory supplements: No restriction. Palmitoylethanolamide (a fatty acid that also damps glial activation), curcumin and long-chain omega-3 fatty acids act on overlapping pathways. Consequence: additive and generally desirable. No dose change is needed.

  • Sedating supplements: Caution. Melatonin and magnesium taken alongside a bedtime dose can add to residual next-morning sedation. Consequence: daytime sedation and impaired alertness. Mitigation: a move to morning dosing rather than a reduction in the sleep supports.

  • Alcohol: Caution. Consequence: reduced reward from alcohol even at low doses, plus additive hepatic load in heavy drinkers. Mitigation: limited intake and liver enzyme testing at 12 weeks.

Populations who should avoid Low-Dose Naltrexone:

  • Anyone taking opioid analgesics, or with any opioid or kratom use in the previous 7–10 days
  • Acute hepatitis, or decompensated cirrhosis at Child-Pugh Class C
  • Pregnancy and breastfeeding, where no controlled human data exist
  • Planned surgery within 72 hours where opioid analgesia is anticipated
  • Chronic kidney disease with an estimated glomerular filtration rate (eGFR, a measure of kidney filtering capacity) below 30 mL/min/1.73 m², until reviewed by a prescriber
  • Anyone currently taking disulfiram for alcohol use disorder

Risk Mitigation Strategies

  • Confirmation of opioid-free status before the first dose: A negative urine opioid screen plus 7–10 days without any opioid, including kratom, prevents precipitated withdrawal — the one serious and entirely avoidable harm.

  • Low starting dose of 0.5–1.5 mg with weekly titration: Beginning at a fraction of the 4.5 mg target and raising by 1–1.5 mg each week limits the vivid dreams, insomnia and nausea that drive most early discontinuation.

  • Morning dosing where sleep is disturbed: Morning dosing preserves the anti-inflammatory effect in clinical practice while removing the overnight receptor blockade responsible for dream intensity and delayed sleep onset.

  • Liver enzyme testing at baseline, 12 weeks and annually: Alanine and aspartate aminotransferase testing detects the dose-related enzyme elevation documented at higher naltrexone doses before it becomes clinically meaningful.

  • Documentation of the prescription: A wallet card or medical-alert entry ensures emergency clinicians and anaesthetists know opioid analgesia will be blocked, preventing inadequate pain control after injury or surgery.

  • Thyroid function recheck every 6–12 weeks on replacement: Thyroid-stimulating hormone monitoring catches the over-replacement that can follow improving thyroid function, preventing palpitations, heat intolerance and accelerated bone loss.

  • A defined trial period with a stopping rule: Committing to 12 weeks against a pre-agreed outcome measure prevents indefinite use without benefit, the commonest pattern behind long-term non-response.

Therapeutic Protocol

  • Standard protocol: Most prescribers follow the trial pattern: 4.5 mg once daily, immediate-release, compounded. Titration from 1.5 mg over 2–4 weeks is near-universal in practice, though the trials themselves mostly started at the full dose.

  • Competing approaches: Integrative practitioners often settle patients at 2.5–3 mg and use liquid formulations for sub-milligram steps; academic pain clinics typically use fixed 4.5 mg capsules. Neither approach has been tested against the other.

  • Who popularised each: The bedtime 3–4.5 mg schedule descends from Bernard Bihari’s 1980s New York practice. The fixed 4.5 mg trial protocol comes from Jarred Younger and Sean Mackey at Stanford and Jill Smith at Penn State.

  • Best time of day: Bedtime dosing was chosen to coincide with the overnight endorphin peak. Morning dosing is increasingly used because it avoids dream and sleep disruption. No trial has compared the two directly.

  • Half-life: Naltrexone’s plasma half-life is roughly 4 hours and that of its active metabolite 6-β-naltrexol roughly 13 hours, which is why a small dose produces only a brief window of receptor blockade.

  • Single versus split dosing: A single daily dose is standard, since the transient blockade is central to the proposed mechanism. Splitting into two smaller doses is reserved for people who cannot tolerate a single dose.

  • Genetic considerations: No pharmacogenetic test guides dosing. The OPRM1 A118G variant and glucuronidation-enzyme variants are plausible modifiers of exposure and response but have not been studied at these doses.

  • Sex differences: Dosing is not adjusted by sex. Because the fibromyalgia trials enrolled almost only women, the 4.5 mg figure is best supported in women; men receive the same dose by extrapolation.

  • Age considerations: Above 65, prescribers commonly start at 0.5–1 mg and titrate more slowly, reflecting reduced hepatic clearance, greater sleep fragility and a higher likelihood of concurrent opioid prescriptions.

  • Baseline biomarkers: A raised erythrocyte sedimentation rate before treatment predicted response in the fibromyalgia pilot. Some clinics use it to select candidates, although the finding has never been replicated.

  • Pre-existing conditions: Treated hypothyroidism, chronic kidney disease and prior liver injury each argue for slower titration and closer laboratory follow-up rather than for avoiding the drug outright.

Discontinuation & Cycling

  • Duration of use: Neither lifelong nor short-course by design. Trials ran 8 to 52 weeks; clinical practice treats it as continuous while a condition remains active, with periodic reassessment rather than a fixed endpoint.

  • Withdrawal effects: None described. Naltrexone is an antagonist rather than an agonist, so stopping produces no physical dependence syndrome. Symptoms of the underlying condition may return over days to weeks.

  • Tapering: Not required pharmacologically. Some practitioners step down over 2–4 weeks to distinguish genuine return of symptoms from expectation effects, which is a diagnostic manoeuvre rather than a safety measure.

  • Cycling: Not supported by evidence. Schedules such as five days on and two off circulate in patient communities, but no trial has examined tolerance, and the 12-month Spanish trial reported no loss of effect over time.

Sourcing and Quality

  • Compounding is unavoidable: No manufacturer makes a 1–4.5 mg product. Doses come from a compounding pharmacy that dilutes 50 mg tablets or bulk powder, so pharmacy quality directly determines dose accuracy and consistency.

  • Accreditation to look for: A 503A compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board and compliant with United States Pharmacopeia chapter 795 for non-sterile preparations is the reference standard; reputable compounders release potency testing records on request.

  • Formulation must be immediate-release: Slow-release or sustained-release capsules defeat the proposed mechanism, which depends on brief receptor blockade followed by recovery. Prescriptions therefore name immediate-release capsules or an aqueous suspension explicitly.

  • Filler choice: Many prescribers avoid calcium carbonate as a filler on absorption grounds and request microcrystalline cellulose or an equivalent. Lactose-free fillers matter for people who are lactose intolerant.

  • Liquid formulations for fine titration: A 1 mg per mL suspension allows 0.25 mg steps that capsules cannot deliver, which matters for people who react strongly to the first dose or who need sub-milligram maintenance.

  • Unregulated overseas supply: Products bought online without a prescription carry no verified potency or identity. Because this is a prescription medicine, legitimate supply always runs through a prescriber and a licensed pharmacy.

  • Named compounders: Skip’s Pharmacy in Florida and Belmar Pharma Solutions in Colorado are long-established compounders frequently named by prescribers; that reflects familiarity with the preparation, not demonstrated superiority.

Practical Considerations

  • Time to effect: Some report change within days; the trials measured outcomes at 8 to 12 weeks. Clinical practice allows a 12-week trial before judging, and up to six months in autoimmune conditions.

  • Common pitfalls: Starting at the full 4.5 mg, abandoning after two weeks of vivid dreams, taking it alongside opioid analgesics, and failing to tell a surgeon or anaesthetist before a procedure.

  • Regulatory status: Entirely off-label. Approved naltrexone products are the 50 mg tablet, a monthly extended-release injection and a fixed bupropion combination; the low-dose preparation is a compounded product with no regulatory approval anywhere.

  • Cost and accessibility: Roughly 35 to 60 US dollars a month, rarely covered by insurance because compounded off-label products are usually excluded. The main access barrier is finding a willing prescriber, not price.

  • Payer incentives run against it: At under 60 dollars a month it is far cheaper than biologics or branded nerve-pain drugs, yet insurers exclude compounded off-label products, so no payer has funded the trials that would place it in guidelines.

Interaction with Foundational Habits

  • Sleep: Direct and usually negative early on. Blocking opioid receptors during the overnight endorphin peak produces vivid dreams in roughly two and a half times as many people as placebo and delays sleep onset. Moving the dose to the morning resolves it; some report deeper sleep once the first weeks pass.

  • Nutrition: No direct interaction. Absorption is unaffected by food and no nutrient is depleted. An anti-inflammatory dietary pattern acts on the same inflammatory signalling and is used alongside rather than instead. Alcohol reward is blunted even at low doses, which some find useful and others unwelcome.

  • Exercise: Potentially blunting, on mechanism rather than measurement. Endogenous opioids are one proposed contributor to post-exercise mood elevation, and receptor blockade could damp it, though a controlled trial found exercise-induced pain relief persists under 50 mg naltrexone. No trial has measured training adaptation, strength gain or perceived exertion on this drug.

  • Stress management: Indirect. The endogenous opioid system participates in social reward and stress buffering, so blockade might theoretically flatten those responses, though the mouse work on proopiomelanocortin neurons found no such change. Practices that lower inflammatory load complement rather than conflict with the drug.

Monitoring Protocol & Defining Success

The baseline work-up begins with confirmation that no opioid — prescription, over-the-counter or botanical — has been taken in the previous seven to ten days, with a urine opioid screen where there is doubt. A baseline liver panel, complete blood count, an inflammatory marker and, for anyone on thyroid replacement, thyroid-stimulating hormone and free thyroxine complete the picture. A numeric pain score and a symptom questionnaire recorded at baseline are what make later judgement possible.

Ongoing monitoring is light: liver enzymes and the inflammatory marker at 12 weeks, then annually; thyroid function every 6 to 12 weeks for anyone on replacement, because settling thyroid inflammation can make a previously correct dose excessive. Symptom scores are repeated at 4 and 12 weeks, when the decision to continue or stop is made.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 10–26 U/L (women), 10–30 U/L (men) Detects the dose-related liver enzyme rise documented at higher naltrexone doses ALT is alanine aminotransferase, a liver enzyme. Conventional laboratory upper limits run to 40–55 U/L, well above the functional target. Fasting is not required.
AST 10–26 U/L Paired with ALT to separate liver from muscle sources of enzyme release AST is aspartate aminotransferase. Conventional laboratory upper limits run to about 40 U/L, well above the functional target. It rises after intense exercise, so results within 48 hours of heavy training are unreliable.
hs-CRP Below 0.5 mg/L Tracks the systemic inflammation the drug is intended to lower hs-CRP is high-sensitivity C-reactive protein. The conventional cardiovascular cut-off is below 1.0 mg/L. Recent infection or injury invalidates the result.
ESR Below 10 mm/hour (men), below 15 mm/hour (women) A higher baseline value tracked with larger benefit in the fibromyalgia pilot ESR is erythrocyte sedimentation rate. Conventional ranges widen with age. Best paired with hs-CRP, which responds faster to change.
TSH 1.0–2.0 mIU/L Detects over-replacement once autoimmune thyroid inflammation settles TSH is thyroid-stimulating hormone. The conventional range extends to 4.5 mIU/L. Best drawn in the morning, before the levothyroxine dose.
Free T4 1.0–1.5 ng/dL Confirms that a change in TSH reflects true thyroid status rather than assay drift Free T4 is unbound thyroxine, the main circulating thyroid hormone. The conventional range runs to about 0.8–1.8 ng/dL. Best paired with free T3 (triiodothyronine, the active form), on the same morning draw as TSH.
Urine opioid screen Negative Confirms opioid-free status before the first dose, preventing precipitated withdrawal Standard panels detect prescription opioids but miss fentanyl, kratom and some synthetics, so history-taking is needed alongside testing.
Fasting insulin Below 5 µIU/mL Baseline for the metabolic effects proposed from animal work Requires 10–12 hours fasting. Conventional laboratories flag nothing below 25 µIU/mL. Best paired with fasting glucose for context.
Symptom score (0–10 numeric rating scale) No established target; track change from the individual’s own baseline, treating a 2-point fall as meaningful The only measure that determines whether treatment continues Recorded daily for one week at baseline rather than as a single reading, since recall bias distorts one-off estimates.

Qualitative markers worth tracking alongside the laboratory values:

  • Dream intensity and dream recall during the first four weeks — the earliest sign the drug is pharmacologically active
  • Sleep-onset latency and the number of night wakings
  • Morning stiffness, and how long it takes to loosen after waking
  • Mental clarity — word-finding, reading endurance, capacity for sustained work
  • Energy through the afternoon, and how long recovery takes after physical exertion
  • Overall impression of change, recorded monthly on a simple better, same or worse scale

Emerging Research

  • Post-viral fatigue, factorial design: The Life Improvement Trial (NCT06366724) randomises 160 people with myalgic encephalomyelitis, chronic fatigue syndrome or long COVID to pyridostigmine, low-dose naltrexone, both, or placebo, with functional capacity as primary endpoint. Phase 2, Brigham and Women’s Hospital.

  • Dose-finding in chronic fatigue: A phase 2 study at the University of Alabama at Birmingham (NCT07285473) will assign 75 participants to blinded doses of 1.5 to 6 mg to identify which best reduces fatigue. Not yet recruiting.

  • Painful diabetic nerve damage: A phase 2 trial at Dartmouth-Hitchcock (NCT04678895) tests 4.5 mg against placebo in 35 participants, with pain disability and numeric pain rating as co-primary endpoints — the first placebo-controlled test in peripheral rather than centralised pain.

  • Complex regional pain syndrome: A Stanford trial (NCT02502162) enrolling 120 participants has been recruiting since 2015, with change in pain severity as primary outcome. Its slow accrual illustrates how little funding reaches trials of an off-patent compound.

  • Longevity combination pilot: A commercial pilot (NCT07475546) run by AgelessRx, which sells these prescriptions, randomises 30 adults aged 60–80 to low-dose naltrexone with metformin, rapamycin and other agents. The combination design prevents attributing any effect to naltrexone alone.

  • Evidence that could weaken the case: Two adequately powered trials — the Danish FINAL trial (Due Bruun et al., 2024) and the Spanish INNOVA trial (Rodríguez-Freire et al., 2026) — found no separation from placebo in fibromyalgia over 12 weeks and 12 months respectively.

  • Geroscience direction: Li et al., 2024 reported lifespan extension in a nematode through the SKN-1 stress-response pathway, while Metz et al., 2021 undercut the endorphin-rebound explanation. Resolving the mechanism determines whether a human longevity effect is plausible at all.

Conclusion

Low-dose naltrexone is a very small amount of an old, inexpensive prescription medicine taken once a day. Its interest lies in what the brief blocking of the body’s own opioid signals appears to set off: quieter inflammatory signalling in the nervous system and a shift in immune activity toward balance. That idea has been carried much further in clinical practice than in the published human record.

The clearest human signal is in active Crohn’s disease, where a small controlled study showed both symptom improvement and visible healing of the bowel lining. For widespread muscle pain the picture is genuinely split — several small studies favoured the drug, and the two largest and longest did not. For lingering illness after infection, inflammatory skin conditions and nerve pain, most reports are encouraging but come from studies with no comparison group. Mood was tested twice with opposite results. Claims relating to lifespan itself rest entirely on worm and mouse work.

Set against that, the safety record is unusually reassuring: sleep disturbance and vivid dreams early on, some nausea, and little else once the trial results are combined. The serious hazard is not the drug itself but the way it blocks opioid pain relief outright.

The evidence base carries its own distortion. Because the compound is off patent, no manufacturer has reason to fund large trials, while the clinics, compounding pharmacies and telehealth companies that promote it earn revenue from its use. Both facts belong in any reading of this literature.

Top - Benefits - Risks - Protocol